In Croatia, three international leaders in Alzheimer’s discuss ongoing clinical trials and global dementia policy ahead of the G8 Dementia Research Summit in London next week

Dec 06 - 2013 04:26 PM

Professor Claude Wischik, Chairman of TauRx Therapeutics, Marc Wortmann, Executive Director of Alzheimer’s Disease International (ADI), and Prof. Ninoslav Mimica, President of Alzheimer Croatia, provide the latest news about ADI’s global dementia policy and the Croatian launch of a global Alzheimer’s Research Study

Phase 3 clinical studies targeting tau aggregation get underway in Korea

Oct 04 - 2013 05:35 AM

Professor Wischik speaks at annual psychogeriatric conference in Korea

TauRx achieves milestone in global Phase 3 clinical trials of LMTX™ for Alzheimer's Disease

Sep 19 - 2013 10:33 PM

Over 300 patients now enrolled worldwide in clinical trials for a second?generation tau aggregation inhibitor (TAI) aimed at halting the progression of Alzheimer’s

In Toronto, Two International Leaders Share One Goal: Slow or Halt the Progression of Alzheimer’s Disease with the Launch of Phase 3 Clinical Trials

Jun 11 - 2013 09:53 PM

Professor Claude Wischik, Executive Chairman of TauRx Therapeutics and Dr. Sharon Cohen, Medical Director of the Toronto Memory Program Announce the Canadian Launch of Pivotal Alzheimer’s Research

First UK patients enroll in Phase 3 clinical trials of LMTX™ for Alzheimer’s Disease

May 22 - 2013 01:00 PM

Clinical trials get under way in the UK with a second?generation tau aggregation inhibitor (TAI) aimed at halting the progression of Alzheimer’s

First
<
1
2
3
4
5
6
7
8
9
10
>
Last

Press Releases

In Croatia, three international leaders in Alzheimer’s discuss ongoing clinical trials and global dementia policy ahead of the G8 Dementia Research Summit in London next week

Phase 3 clinical studies targeting tau aggregation get underway in Korea

TauRx achieves milestone in global Phase 3 clinical trials of LMTX™ for Alzheimer's Disease

In Toronto, Two International Leaders Share One Goal: Slow or Halt the Progression of Alzheimer’s Disease with the Launch of Phase 3 Clinical Trials

First UK patients enroll in Phase 3 clinical trials of LMTX™ for Alzheimer’s Disease